X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs TORRENT PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA TORRENT PHARMA SANOFI INDIA/
TORRENT PHARMA
 
P/E (TTM) x 34.6 37.6 91.9% View Chart
P/BV x 6.9 5.9 118.4% View Chart
Dividend Yield % 1.3 0.9 139.9%  

Financials

 SANOFI INDIA   TORRENT PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
TORRENT PHARMA
Mar-17
SANOFI INDIA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs4,5601,768 257.9%   
Low Rs4,4001,186 371.1%   
Sales per share (Unadj.) Rs1,028.5346.1 297.2%  
Earnings per share (Unadj.) Rs129.055.2 233.8%  
Cash flow per share (Unadj.) Rs186.073.3 253.7%  
Dividends per share (Unadj.) Rs68.0014.00 485.7%  
Dividend yield (eoy) %1.50.9 160.1%  
Book value per share (Unadj.) Rs753.6257.1 293.2%  
Shares outstanding (eoy) m23.03169.22 13.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.44.3 102.1%   
Avg P/E ratio x34.726.8 129.8%  
P/CF ratio (eoy) x24.120.1 119.6%  
Price / Book Value ratio x5.95.7 103.5%  
Dividend payout %52.725.4 207.8%   
Avg Mkt Cap Rs m103,174249,887 41.3%   
No. of employees `0003.611.8 30.8%   
Total wages/salary Rs m3,5929,934 36.2%   
Avg. sales/employee Rs Th6,537.74,971.5 131.5%   
Avg. wages/employee Rs Th991.4843.2 117.6%   
Avg. net profit/employee Rs Th819.8792.4 103.4%   
INCOME DATA
Net Sales Rs m23,68658,569 40.4%  
Other income Rs m7082,233 31.7%   
Total revenues Rs m24,39460,802 40.1%   
Gross profit Rs m5,28113,773 38.3%  
Depreciation Rs m1,3133,069 42.8%   
Interest Rs m152,056 0.7%   
Profit before tax Rs m4,66110,881 42.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6911,545 109.4%   
Profit after tax Rs m2,9709,336 31.8%  
Gross profit margin %22.323.5 94.8%  
Effective tax rate %36.314.2 255.5%   
Net profit margin %12.515.9 78.7%  
BALANCE SHEET DATA
Current assets Rs m15,67353,841 29.1%   
Current liabilities Rs m6,67831,612 21.1%   
Net working cap to sales %38.038.0 100.1%  
Current ratio x2.31.7 137.8%  
Inventory Days Days7697 78.2%  
Debtors Days Days2284 26.6%  
Net fixed assets Rs m8,09842,079 19.2%   
Share capital Rs m230846 27.2%   
"Free" reserves Rs m17,08842,655 40.1%   
Net worth Rs m17,35643,501 39.9%   
Long term debt Rs m022,408 0.0%   
Total assets Rs m25,400101,250 25.1%  
Interest coverage x311.76.3 4,953.4%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.90.6 161.2%   
Return on assets %11.811.3 104.5%  
Return on equity %17.121.5 79.7%  
Return on capital %26.919.6 137.3%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,14520,066 35.6%   
Fx outflow Rs m6,8465,304 129.1%   
Net fx Rs m29914,762 2.0%   
CASH FLOW
From Operations Rs m3,22610,127 31.9%  
From Investments Rs m-1,555-7,869 19.8%  
From Financial Activity Rs m-1,818-1,918 94.8%  
Net Cashflow Rs m-147212 -69.5%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 7.0 205.1%  
FIIs % 14.6 12.6 115.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.8 119.3%  
Shareholders   15,184 26,511 57.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  PLETHICO PHARMA  GLENMARK PHARMA  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 99 Points Down; Vedanta & Coal India Top Losers(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.9% while the Hang Seng is down 2%. The Shanghai Composite is trading down by 2.7%.

Related Views on News

TORRENT PHARMA at 52 Week High; BSE 500 Index Down 0.3 %

Jun 19, 2018 | Updated on Jun 19, 2018

TORRENT PHARMA share price has hit a 52-week high. It is presently trading at Rs 1,524. BSE 500 Index is down by 0.27% at 14,773. Within the BSE 500, TORRENT PHARMA (up 2.80%) and RELAXO FOOTWEARS (up 5.86%) are among the top gainers, while top losers are MANPASAND BEVERAGES and KRBL LIMITED.

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jun 19, 2018 10:29 AM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS